Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2008

View Archived Issues

Novel agents for asthma and other respiratory disorders reported in recent patents

Enhanced effects seen with combination of radiotherapy and AZD-6244 in lung cancer model

Experiments with caprospinol reveal potentially useful effects against Alzheimer's disease

Arete describes new antihypertensive agents in a recent patent

Recent GSK, Ranbaxy and Schering patents disclose novel antimicrobial agents

Beneficial effects of iNOS inhibitors demonstrated in experimental COPD

URL submits NDA to the FDA for colchicine tablets in gout flares

MJFF awards USD 2 million grant to research projects on cognitive deficits in PD

FDA to review Arpida's NDA for iclaprim in cSSSI in November 2008

Synta receives USD 25 million milestone payment from GSK under elesclomol collaboration

RXi licenses rights from UMMS to technology for oral delivery of RNAi therapeutics

Lilly initiates cash tender offer for ImClone at USD 70 per share

Aradigm completes enrollment in phase II study of inhaled liposomal ciprofloxacin

Regado completes enrollment in REVERSAL-PCI phase IIa clinical study of REG1

Inhibiting FtsZ protein shows potential anti-staphylococcal activity in experimental model

Addex completes the first part of a two-part phase I ADX-48621 trial

Akorn launches Akten Gel 3.5% as a topical ocular anesthetic

Almirall and Forest to progress the development of aclidinium bromide

Avigen initiates exploratory study of AV-411 in opioid withdrawal

ChemoCentryx advances oral CCR9 antagonist CCX-025 into the clinic

BioMarin presents phase IIa results for 6R-BH4 in sickle cell disease

Palifosfamide receives positive opinion for E.U. orphan product designation

Sirion launches Durezol for postoperative ocular inflammation and pain

R&D highlights from the UBS Global Life Sciences Conference in New York: Oxford BioMedica

Lapatinib shows encouraging activity in phase II SCCHN study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.